/PRNewswire/ Cadence Neuroscience announced today that it has secured $26 million in Series B financing. The round was led by Angelini Lumira Biosciences.
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance. Financial
LivaNova PLC , a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.
Financial Summary and. | May 3, 2023
The 34-page OFCCP full fiscal year (“FY”) 2024 Congressional Budget Justification (“CBJ”) revealed key aspects of the agency’s future plans and past performance metrics. We reported.
22.02.2023 - LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023. Fourth-Quarter Financial Summary and Highlights1 .